By Chris Wack
American depositary receipts of DBV Technologies gained after the company reported new financing of up to $306.9 million.
The biopharmaceutical company's ADRs were up 57%, at $6.14, Friday morning. They have risen about 99% since the beginning of the year.
Earlier in the week, DBV Technologies, which is developing the Viaskin patch for the treatment of pediatric peanut allergy, said its cash would likely run out after next month, casting doubt about its ability to continue as a going concern.
The new money--which includes proceeds of $125.5 million to be received upon closing, and up to $181.4 million if all the warrants are exercised--tied to specific conditions, such as DBV's Phase 3 study hitting its primary endpoint.
The Montrouge, France, company expects that the proceeds would be used for working capital and general corporate purposes, to finance the continued development of the Viaskin Peanut program, to finance the preparation and submission of a potential Biologics License Application and to finance the readiness of a launch of Viaskin peanut in the U.S., if approved.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 28, 2025 11:09 ET (15:09 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。